Encoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
ParticipantFC
Farallon Capital Management
Activity from announced rounds
Activity in this selectionUnited States · Oct 23, 2026 · Jan 1, 2026
Farallon Capital Management is the investment manager identified by Encoded Therapeutics and HiBob, with Farallon also used as a short name.
Recorded funding activity
Encoded develops precision gene therapies for neurological disorders. HiBob supplies the Bob people-management platform, while Mirador develops medicines for inflammatory and fibrotic diseases. Their financing events retain the same manager identity without collapsing individual funds.
- Rounds participated in
- 3
- Confirmed lead rounds
- 0 2 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $830M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionMirador Therapeutics
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
$250MSeries B
Role not disclosedParabilis Medicines
Develops medicines targeting historically undruggable protein targets in cancer
$305MSeries F
Role not disclosed